REFERENCES
- el-Guebaly N., Cathcard J., Currie S., Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatric Services. 2002; 53: 1166–1170
- Fiore M. C., Bailey W. C., Cohen S. J., Dorfman S. F., Goldstein M. G., Gritz E. R., et al. Treating tobacco use and dependence: Quick reference guide for clinicians. U.S. Dpartment of Health and Human Services. Public Health Service, Maryland 2000
- Gonzales D., Rennard S., Nides M., Oncken C., Azoulay S., Billing C. B., et al. Varenicline, an a4 b2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial for the varenicline phase 3 study group. Journal of the American Medical Association 2006; 296: 47–55
- Pfizer Pharmaceutical Company. CHANTIX™ (Varenicline) Prescribing information. May, 2006, Publication LAB-0327-2.0
- Ranney L., Melvin C., Lux L., McClain E., Lorh K. N. Systematic review: Smoking cessation intervention strategies for adults and adults in special populations. Annals of Internal Medicine 2006; 145(11)845–856
- Stahl S. Essential psychopharmacology: Neuroscientific basis and practical applications, 2nd ed. Cambridge University Press, New York 2000
- Stahl S. Essential psychopharmacology: The prescriber's guide, 2nd ed. Cambridge University Press, New York 2005